sub:assertion {
  d:DB05098 v:identifier "DB05098" ;
    v:namespace "drugbank" ;
    v:uri "http://bio2rdf.org/drugbank:DB05098" ;
    v:x-identifiers.org <http://identifiers.org/drugbank/DB05098> ;
    dv:drugbank-id "DB05098" ;
    dv:x-cas <http://bio2rdf.org/cas:169494-85-3> ;
    dv:x-wikipedia <http://bio2rdf.org/wikipedia:Leptin> ;
    dct:description "Although leptin is a circulating signal that reduces appetite, in general, obese people have an unusually high circulating concentration of leptin. These people are said to be resistant to the effects of leptin, in much the same way that people with type 2 diabetes are resistant to the effects of insulin. Thus, obesity develops when people take in more energy than they use over a prolonged period of time, and this excess food intake is not driven by hunger signals, occurring in spite of the anti-appetite signals from circulating leptin. The high sustained concentrations of leptin from the enlarged fat stores result in the cells that respond to leptin becoming desensitized."@en ;
    dct:identifier "drugbank:DB05098" ;
    dct:title "Leptin"@en ;
    a dv:Drug ;
    rdfs:label "Leptin [drugbank:DB05098]"@en ;
    rdfs:seeAlso <http://www.drugbank.ca/drugs/DB05098> .
}